Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling (LD-VenEx)

Phase II Study of Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With Acute Myeloid Leukemia With Integration of Explorative Multi-omics and ex Vivo Drug Screening Data

Multi-center phase II study of standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of "low-dose" venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia.

AZA and LD-VEN treatment is combined with exploratory AML profiling using established platforms for OMICs analyses and ex vivo drug sensitivity and resistance testing. This will validate the feasibility of AML profiling in a clinical setting to predict responders and non-responders to AZA/LD-VEN therapy. The exploratory AML profiling program will also identify biomarkers as well as novel drugs and drug combinations applicable for treatment of AML patients in future clinical trial initiatives.

Study Overview

• Status: Recruiting
• Conditions: Acute Myeloid Leukemia
• Intervention / Treatment: Drug: Venetoclax

Detailed Description

Multi-center phase II study of standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of "low-dose" venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia.

AML patients will be subjected to conventional diagnostic workup to assess if they fulfil eligibility criteria. As part of the exploratory trial program, bone marrow (BM) and peripheral blood (PB) samples will be subjected to functional AML profiling including OMICs analyses and immediate ex vivo drug sensitivity and resistance testing (DSRT). The treatment period with AZA/LD-VEN begins after completion of the diagnostic workup period, and includes drug treatment, clinical assessment, QoL assessment, and analysis of relevant follow-up BM and PB samples according to a detailed study event schedule. Patients will receive repeated cycles of treatment with AZA (D1-D7, 75mg/m2 qd) in combination with LD-VEN (D1-D14 before CR and D1-D7 after CR, 400mg qd) every 4 weeks. Patients exhibiting clinical response will continue treatment with AZA/LD-VEN for a maximum of two years or until withdrawal of consent, disease progression, unacceptable toxicity, intolerance, lack of compliance, unresponsiveness after three cycles of study treatment, or if they obtain CR and proceed to allogeneic stem cell transplantation. Clinical response (CR/CRi/MLFS=morphologic leukemia-free state/PR=partial remission), survival information (OS/DOR=duration of response/EFS=event-free survival), and QoL data will be collected for all patients independently on their response to AZA/LD-VEN treatment. Survival information and post-treatment follow-up (i.e. all post-treatment AML therapies including dates of initiation and completion, the date and cause of death) will be collected every three months for the first two years and thereafter annually for the following three years after End-Of-Treatment or withdrawal from study treatment, or until death of the patient.

The exploratory program will validate the feasibility of comprehensive OMICs profiling and ex vivo drug sensitivity and resistance testing in a clinical setting to predict responders and non-responders to AZA/LD-VEN therapy. The exploratory AML profiling program is expected to identify biomarkers as well as novel drugs and drug combinations applicable for treatment of AML patients that are refractory or suffer from relapse after AZA/LD-VEN treatment in future clinical trial initiatives.

• Study Type: Interventional
• Enrollment (Anticipated): 117
• Phase: Phase 2

Contacts and Locations

• Study Contact: Name: Kim Theilgaard-Mönch, MD, DMSc; Phone Number: +4535455197; Email: kim.theilgaard-moench@regionh.dk
• Study Contact Backup: Name: Anne Louise Tølbøll Sørensen, MD, PhD; Phone Number: +4535451864; Email: anne.louise.toelboell.soerensen@regionh.dk

Study Locations

• Denmark
  • Copenhagen, Denmark, 2100
    • Recruiting
    • Department of Hematology, Rigshospitalet
    • Contact: Mette H Thrane, Master of Public Health; Phone Number: +4535450944; Email: mette.hoejmose.thrane.01@regionh.dk
    • Contact: Julie Palmer Rohold, MSc; Phone Number: +4535455111; Email: julie.palmer.rohold@regionh.dk
    • Principal Investigator: Kim Theilgaard-Mönch
    • Principal Investigator: Anne Louise T Sørensen

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Written informed consent.

• Patients who present with one of the following (except acute promyelocytic leukemia).

  1. De novo or secondary AML unfit for standard induction therapy
  2. Relapsed/refractory AML after at least 1 line of prior therapies

• Written informed consent to participate in an exploratory research protocol including bio-banking, comprehensive AML profiling (genomics, transcriptomics, proteomics, etc.) and ex vivo drug sensitivity testing to assess venetoclax and other drug sensitivities.

  a) All patients are treated with azacitidine+venetoclax irrespective of the ex vivo screening results.

• ECOG Performance status ≤ 2 for patients ≥ 75 years of age OR ≤ 3 for patients ≥ 18 to 74 years of age.
• Leukocyte count < 25 x10E9/l. Hydroxyurea use is permitted to meet this criterion
• Adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL/min; determined by the Cockcroft Gault formula.

• Adequate liver function as demonstrated by

  1. alanine aminotransferase (ALT) ≤ 4.0 × ULN.
  2. bilirubin ≤ 1.5 × ULN.

• Specific inclusion criteria for elderly/unfit AML patients:

  1. ≥ 70 years of age OR

  2. ≥ 18 to 69 years of age and ineligible for intensive chemotherapy meeting at least one of the following criteria:

     • Clinically significant comorbidities, as reflected by at least 1 of the following criteria:

       • Left ventricular ejection fraction (LVEF) < 50%.
       • Lung diffusion capacity for carbon monoxide (DLCO) ≤ 65% of expected.
       • Forced expiratory volume in 1 second (FEV1) ≤ 65% of expected.
       • Chronic stable angina or congestive heart failure controlled with medication.
       • Alanine aminotransferase (ALT) 3.0-4.0 × ULN.
     • Other contraindication(s) to anthracycline therapy (must be documented).
     • Adverse risk genetics (ELN criteria) associated with poor outcome with standard chemotherapy.
     • Patient declines intensive chemotherapy.
     • Secondary AML after previous disease modifying treatment (i.e. HMA/induction chemotherapy and/or allogeneic stem cell transplantation) of clonal myeloid diseases such as MDS, MDS/MPN, or MPN.

• Specific inclusion criteria for relapsed AML patients:

  1. ≥ 55 years of age with non-CBF AML relapse OR

  2. ≥ 18 of age and meeting at least one of the following criteria:

     • Not candidate for intensive chemotherapy (see criterion 8).
     • Relapse after chemotherapy, or monotherapy with HMA, or allogeneic stem cell transplantation. (note: patients with 4th or higher relapse are excluded).
     • Patient declines intensive chemotherapy.
• Specific inclusion criteria for refractory AML patients:

Patients who fail to achieve a complete or partial remission after previous monotherapy with HMA or induction chemotherapy (at least 1 cycle of chemotherapy containing cytarabine or clofarabine, in combination with a topoisomerase II inhibitor (e.g. anthracycline or mitoxantrone).

Exclusion Criteria:

• Acute promyelocytic leukemia (APL).
• Patients with 4th or higher AML relapse.
• Leukemic cell content (blast percentage) in bone marrow/peripheral blood < 10 %.
• ECOG >3.
• Prior venetoclax treatment for myeloid malignancy.
• AML patients with CNS involvement (note: cerebrospinal fluid or radiological investigations are not required without clinical suspicion).
• HIV infection or active hepatitis B virus (HBV), or hepatitis C virus (HCV) infection that is not controlled with antiviral medication with the definition hereof at the discretion of the investigator.
• Cardiovascular disability status of New York Heart Association Class ≥ 2. Class 2 is defined as cardiac disease in which patients are comfortable at rest but ordinary physical activity results in palpitations, fatigue, dyspnea, or anginal pain.

• Evidence of clinically significant condition(s), which at the investigator's discretion would adversely affect the patient's participation in this study (including but not limited to):

  1. Chronic respiratory disease that requires continuous oxygen use.
  2. Systemic uncontrolled infection requiring therapy (viral, bacterial or fungal).
  3. Malabsorption syndrome or other condition that precludes enteral route of administration.
  4. Uncontrolled GVHD.
• Previous malignancies with the exception of previous malignancy treated successfully with curative intent and indolent/smoldering malignancies (defined at the investigator's discretion).
• Pregnant women and nursing mothers (a negative pregnancy test is required for all women of childbearing potential within 7 days before start of treatment).

• Fertile men or women of childbearing potential unless:

  1. Surgically sterile or ≥ 2 years after the onset of menopause.
  2. Willing to use two methods of reliable contraception including one highly effective contraceptive method (Pearl Index <1) and one additional effective (barrier) method during study treatment and for 3 months after the end of study treatment.
• Known hypersensitivity to venetoclax or azacitidine or excipients of any of the drugs.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: TREATMENT
• Allocation: NA
• Interventional Model: SINGLE_GROUP
• Masking: NONE

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Elderly/unfit AML patients or sec. and R/R AML patients	Drug: Venetoclax; Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd) in combination with a short duration of "low-dose" venetoclax treatment (LD-VEN; D1-D14 before CR and D1-D7 after CR, 400mg qd) per 28 days cycle for elderly/unfit (arm 1) and relapsed/refractory (arm 2) patients with acute myeloid leukemia.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall response rate	ORR(%) = CR rate(%)+CRi rate(%)+MLFS(%)	1-1,5 year
Composite complete remission rate	Composite CR rate (%) = CR rate (%) + CRh rate (%)	1-1,5 year
Partial remission rate	PR rate (%)	1-1,5 year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Overall survival	Overall survival (OS) (months)	3,5-5 years
Duration of response	Duration of response (DOR) (months)	3,5-5 years
Event free survival	Event free survival (EFS) (months)	3,5-5 years
Frequency and severity of adverse events	Frequency and severity of adverse events (hematologic toxicities-AE grade 3+4, febrile neutropenia, days until neutrophil recovery ≥ 0.5 x 10E9/l and platelet recovery ≥ 50 x 10E9/l, severe AE grade 3+4).	3-3,5 years
The correlation of ex vivo drug sensitivity with specific clinical responses	The correlation of ex vivo drug sensitivity with specific clinical responses (OS, DOR, EFS, MRD status).	1,5-2 years
The correlation of venetoclax blood concentrations with specific responses	The correlation of venetoclax blood concentrations with specific responses (OS, DOR, EFS, MRD status).	1,5-2 years
Quality-of-Life	Quality-of-Life (QoL) as assessed by European Organization for Research and Treatment of Cancer Quality-of-Life Questionnaire - C30 (EORTC-QLQ-C30), including domains and scale 1-4 - (1) Not at all, (2) a little, (3) quite a bit, (4) very much.	3-3,5 years
Quality-of-Life	Quality-of-Life (QoL) as assessed by European Quality-of-Life - 5 Dimensions - 5 Level (EQ-5D-5L) questionnaire, including EQ-5D domains and visual analogue scale (VAS score 0-100).	3-3,5 years

Collaborators and Investigators

• Sponsor: Rigshospitalet, Denmark
• Collaborators: Vestre Viken Hospital Trust; Karolinska University Hospital; Helsinki University Central Hospital; Oulu University Hospital; Kuopio University Hospital; University Hospital of North Norway; Helse Stavanger HF; Haukeland University Hospital; St. Olavs Hospital; Tampere University Hospital; Skane University Hospital; Helse Møre og Romsdal HF; Uppsala University Hospital

Study record dates

Study Major Dates

• Study Start (ACTUAL): May 24, 2022
• Primary Completion (ANTICIPATED): September 1, 2031
• Study Completion (ANTICIPATED): September 1, 2031

Study Registration Dates

• First Submitted: June 1, 2022
• First Submitted That Met QC Criteria: June 21, 2022
• First Posted (ACTUAL): June 24, 2022

Study Record Updates

• Last Update Posted (ACTUAL): June 24, 2022
• Last Update Submitted That Met QC Criteria: June 21, 2022
• Last Verified: June 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Neoplasms by Histologic Type; Neoplasms; Leukemia; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Antineoplastic Agents; Venetoclax
• Other Study ID Numbers: H-21030117

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No